Improved outcomes of kidney-after-liver transplantation after the implementation of the safety net policy.


Journal

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185

Informations de publication

Date de publication:
29 Nov 2023
Historique:
received: 15 08 2023
accepted: 10 11 2023
medline: 28 11 2023
pubmed: 28 11 2023
entrez: 28 11 2023
Statut: aheadofprint

Résumé

The number of kidney after liver transplants (KALT) increased after the implementation of the UNOS safety net policy but the effects of the policy on KALT outcomes remain unknown. Using the UNOS database, we identified KALT between 60 and 365 days from liver transplant (LT) from 1/1/2010 to 12/31/2020. The main outcome was 1- and 3-year patient, liver and kidney graft survival. Secondary outcomes inlcuded 6-month and 1-year acute rejection (AR) of liver and kidney, and 1-year kidney allograft function. Of the 256 KALT, 90 were pre-policy and 166 post-policy. Compared to pre-policy, post-policy 1- and 3-year liver graft survival was higher (54% and 54% vs. 86% and 81% respectively, p<0.001) while 1- and 3-year kidney graft survival (99% and 75% vs. 92% and 79% respectively, p=0.19), and 1- and 3-year patient survival (99% and 99% vs. 95% and 89% respectively, p=0.11) were not significantly different. Subgroup analysis revealed similar trends in patients with and without renal failure at LT. Liver AR at 6 months was lower post-policy (6.3% vs. 18.3%, p=0.006) but was similar (10.5% vs. 13%, p=0.63) at 1-year. Kidney AR was unchanged post-policy at 6 months and 1-year. Creatinine at 1-year did not differ post- versus pre-policy (1.4 mg/dL vs. 1.3 mg/dL, p=0.07) despite higher proportion of deceased donor, higher kidney donor profile index (KDPI), and longer kidney cold ischemia time post-policy (p<0.05 for all). This 3-year follow-up after the 2017 UNOS policy revision demonstrated that the safety net implementation has resulted in improved liver outcomes for KALT patients with no increased AR of the liver or the kidney allografts.

Sections du résumé

BACKGROUND BACKGROUND
The number of kidney after liver transplants (KALT) increased after the implementation of the UNOS safety net policy but the effects of the policy on KALT outcomes remain unknown.
METHODS METHODS
Using the UNOS database, we identified KALT between 60 and 365 days from liver transplant (LT) from 1/1/2010 to 12/31/2020. The main outcome was 1- and 3-year patient, liver and kidney graft survival. Secondary outcomes inlcuded 6-month and 1-year acute rejection (AR) of liver and kidney, and 1-year kidney allograft function.
RESULTS RESULTS
Of the 256 KALT, 90 were pre-policy and 166 post-policy. Compared to pre-policy, post-policy 1- and 3-year liver graft survival was higher (54% and 54% vs. 86% and 81% respectively, p<0.001) while 1- and 3-year kidney graft survival (99% and 75% vs. 92% and 79% respectively, p=0.19), and 1- and 3-year patient survival (99% and 99% vs. 95% and 89% respectively, p=0.11) were not significantly different. Subgroup analysis revealed similar trends in patients with and without renal failure at LT. Liver AR at 6 months was lower post-policy (6.3% vs. 18.3%, p=0.006) but was similar (10.5% vs. 13%, p=0.63) at 1-year. Kidney AR was unchanged post-policy at 6 months and 1-year. Creatinine at 1-year did not differ post- versus pre-policy (1.4 mg/dL vs. 1.3 mg/dL, p=0.07) despite higher proportion of deceased donor, higher kidney donor profile index (KDPI), and longer kidney cold ischemia time post-policy (p<0.05 for all).
CONCLUSIONS CONCLUSIONS
This 3-year follow-up after the 2017 UNOS policy revision demonstrated that the safety net implementation has resulted in improved liver outcomes for KALT patients with no increased AR of the liver or the kidney allografts.

Identifiants

pubmed: 38015446
doi: 10.1097/LVT.0000000000000302
pii: 01445473-990000000-00292
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 American Association for the Study of Liver Diseases.

Auteurs

Rose Mary Attieh (RM)

Department of Transplant, Mayo Clinic, Jacksonville, Florida.
Division of Kidney Diseases and Hypertension, Department of Medicine, Glomerular Center at Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York.

Ramez M Ibrahim (RM)

Department of Transplant, Mayo Clinic, Jacksonville, Florida.

Peter Ghali (P)

Department of Medicine, Division of Gastroenterology, University of Florida.

Andrew Keaveny (A)

Department of Transplant, Mayo Clinic, Jacksonville, Florida.

Kristopher Croome (K)

Department of Transplant, Mayo Clinic, Jacksonville, Florida.

David Hodge (D)

Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida.

Launia White (L)

Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida.

Hani M Wadei (HM)

Department of Transplant, Mayo Clinic, Jacksonville, Florida.

Classifications MeSH